Korea Institute of Radiological and Medical Sciences

Seoul, South Korea

Korea Institute of Radiological and Medical Sciences

Seoul, South Korea
SEARCH FILTERS
Time filter
Source Type

Provided are a novel compound, in which a bombesin derivative known as having selectivity with respect to prostate cancer bonds with a ligand via aminomethyl galacturonic acid, a complex compound that covalently bonds with a radioactive isotope via the ligand of the novel compound, methods of preparing the compounds, and a nuclear-based molecular imaging agent including the complex compound.


Although Bcl-2 family proteins were originally identified as key regulators of apoptosis, an impressive body of evidence has shown that pro-survival members of the Bcl-2 family, including Bcl-2, Bcl-XL, and Bcl-w, can also promote cell migration, invasion, and cancer metastasis. Interestingly, cell invasion was recently found to be suppressed by multidomain pro-apoptotic members of the Bcl-2 family, such as Bax and Bak. While the mechanisms underlying these new functions of Bcl-2 proteins are just beginning to be studied, reactive oxygen species (ROS) have emerged as inducers of cell invasion and the production of ROS from mitochondrial respiration is known to be promoted and suppressed by the pro-survival and multidomain pro-apoptotic Bcl-2 family members, respectively. Here, I review the evidence supporting the ability of Bcl-2 proteins to regulate cancer cell invasion and metastasis, and discuss our current understanding of their underlying mechanisms, with a particular focus on mitochondrial respiration and ROS, which could have implications for the development of strategies to overcome tumor progression.


Disclosed are a composition including gelsolin as an effective ingredient for inducing differentiation into a dendritic cell, a method of inducing differentiation by using the composition, and a vaccine composition for treating cancer or an immune-mediated disease. In addition, a composition including gelsolin as an effective ingredient for inducing differentiation into a dendritic cell and a method of inducing differentiation into a dendritic cell by treating an immature dendritic cell with gelsolin are also disclosed. Further, a dendritic cell differentiated by using the method of inducing differentiation into the dendritic cell and a vaccine composition including the dendritic cell as an effective ingredient for treating cancer or an immune-mediated disease are disclosed.


Patent
Korea Institute of Radiological and Medical Sciences | Date: 2016-01-20

Provided is an apparatus and method for calculating a correction factor, the apparatus including: a counter configured to acquire first data indicating a counted value of a first radiation source according to an activity and an energy window width, and to acquire second data indicating a coincidence value of a second radiation source according to an activity and an energy window width; and a calculator configured to calculate a correction factor for correcting a difference of the coincidence value of the second radiation source having occurred in response to a single gamma photon emission of the first radiation source, based on the first data and the second data.


Patent
Korea Institute of Radiological and Medical Sciences | Date: 2016-01-11

Provided are a compound represented by Formula I, a pharmaceutically acceptable salt thereof, or a solvate thereof; and a pharmaceutical composition for cancer treatment and a pharmaceutical composition for a radiation sensitizer for cancer treatment, each pharmaceutical composition including the compound of Formula I, the pharmaceutically acceptable salt thereof, or the solvate thereof:


Patent
Korea Institute of Radiological and Medical Sciences | Date: 2016-05-27

According to an aspect of the present disclosure, a method of enhancing neutron high linear-energy-transfer (LET) radiation therapy of cancer is provided, wherein the method includes administering an effective amount of gold nano-particles (GNPs) to a subject that needs neutron high LET radiation therapy of cancer, before or after radiation therapy.


Patent
Korea Institute of Radiological and Medical Sciences | Date: 2015-01-07

Disclosed is an anticancer supplement agent including a benzo[d]oxazole derivative as an effective ingredient. The benzo[d]oxazole derivative, which is a nuclear factor E2-related factor 2 (Nrf2) inhibitor, is capable of inhibiting activity of Nrf2 that induces an antioxidant enzyme to remove reactive oxygen species (ROS) that kills a cancer cell, thereby increasing production of ROS. Therefore, the benzo[d]oxazole derivative can be used as an anticancer supplement agent that shows therapeutic effects in anticancer agent therapy or radiation therapy, and in this regard, the benzo[d]oxazole derivative can overcome tolerance of the cancer cell to anticancer agent therapy or radiation therapy and enhance apoptotic effects on the cancer cell.


Patent
Korea Institute of Radiological and Medical Sciences | Date: 2015-10-23

A thin-layer chromatography type radiation detector includes a plurality of light-emitting members configured to generate visible light due to radiation, each of the light-emitting members including a scintillator having a surface filled with a reflector for reflecting the visible light, and are arranged in parallel to one another in a width direction, light sensors respectively coupled to one end portions of the plurality of light-emitting members and configured to measure a current generated due to the visible light generated by the plurality of light-emitting members, and an output port configured to sequentially output values of the current measured by the light sensors as digital signals.


Patent
Korea Institute of Radiological and Medical Sciences | Date: 2015-06-02

Provided is a polyhedral-shaped radiation counter which measures a radiation level of a radioactive material, in which sensor modules configured to measure the radiation level are disposed at vertexes of a polyhedral shape, respectively, and the sensor modules are connected to each other by rod-shaped frame members disposed in edge positions of the polyhedral shape and face parts of the polyhedral shape form an open space.


Patent
Korea Institute of Radiological and Medical Sciences | Date: 2015-06-23

Disclosed are increased expression of ERp57, ERp57-STAT3 complex, and ERp57-STAT3-Mcl-1 in laryngeal cancer, especially in radioresistant laryngeal cancer and their regulations on radioresistance of laryngeal cancer. As such, the efficacy of radiotherapy can be enhanced by diagnosing prognosis in laryngeal cancer and radioresistance of laryngeal cancer. Furthermore, provided are a method of screening a therapeutic agent for laryngeal cancer including selecting a candidate drug that inhibits the expression of ERp57 or inactivates ERp57, and a therapeutic method for inhibiting or treating laryngeal cancer or radioresistant laryngeal cancer, thereby being useful in the treatment of laryngeal cancer.

Loading Korea Institute of Radiological and Medical Sciences collaborators
Loading Korea Institute of Radiological and Medical Sciences collaborators